Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study describes a man with long-standing alopecia universalis who experienced hair regrowth after taking testosterone, chorionic gonadotropin, and DHEA-S.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

This study found that topical Hair UpTM appeared effective and safe for treating alopecia totalis and alopecia universalis, with high rates of terminal hair regrowth and notable cosmetic acceptability, particularly among minors.

Azathioprine may be an effective treatment for severe hair loss.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

In this case report, a patient with alopecia universalis experienced hair regrowth after clinical islet transplantation, which may indicate the potential impact of immunosuppressive therapy on this autoimmune condition.

This article discusses the expression of vitamin D receptor in hair follicles and its role in alopecia, without presenting new findings; the authors highlight the involvement of Wnt/b-catenin signaling in hair growth.

This abstract reviews published cases indicating a potential association between alopecia areata and Down syndrome, with no new clinical results.

This review discusses the associations between nonscarring alopecia and conditions like vitiligo and autoimmune reactions, but reports no new clinical results.

This study reports promising results for alopecia universalis treatment using a combination of systemic methotrexate and low-dose corticosteroids with topical minoxidil, though monitoring for side effects is necessary.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

In this 1-year study of patients with alopecia areata universalis, researchers found that 0.03% topical bimatoprost led to an acceptable cosmetic response in 43.24% of participants.

In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This case highlights the potential link between type 1 diabetes, pernicious anemia, and alopecia areata universalis, suggesting clinicians should monitor for pernicious anemia in such patients.

This report describes the first documented occurrence of Vohwinkel's disease combined with congenital alopecia universalis in siblings from the same family, both unresponsive to prior treatments.

This report describes a 23-year-old man with alopecia areata universalis who experienced severe nail abnormalities, which improved with systemic steroids, benefiting his work as a card illusionist.

Psoriasis can cause hair growth in areas affected by alopecia areata.

This report describes a rare case of alopecia areata universalis developing in a child during the recovery phase of phenobarbital-induced anti-convulsant hypersensitivity syndrome, which suggests a mechanism involving lymphocyte-related immune responses.

This case report describes a canine with alopecia areata universalis treated with oral ciclosporin, which was associated with hair regrowth, but some areas remained hairless after 17 months.

Topical corticosteroids can help treat severe alopecia areata when other treatments fail.

This report describes a case of alopecia areata returning as AA universalis in a 63-year-old woman after receiving the SARS-CoV-2 vaccine, following a 32-year remission.

This case report suggests an association between the use of Sitagliptin, a DPP-4 inhibitor, and the development of alopecia universalis in a diabetic patient.

This case report details a 46-year-old woman with severe atopic dermatitis and alopecia areata universalis who experienced renewed hair growth and improved skin symptoms after starting dupilumab therapy.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

The man's hair loss and skin papules were diagnosed as atrichia with papular lesions, not alopecia areata universalis.

Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.

In this case report, a 24-year-old North Indian male with type 1 diabetes mellitus presented with alopecia universalis, illustrating the rare simultaneous occurrence of these autoimmune diseases, which are manifestations of multiple endocrine autoimmune syndrome.